Eur Rev Med Pharmacol Sci 2017; 21 (15): 3347-3352
DOI:

Clinical significance of PSMA, TERT and PDEF in malignant tumors of the prostate

J. Situ, H. Zhang, L. Lu, K. Li, C. Hu, D.-J. Wang

Department of Urology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou City, Guangdong Province, China. wdejuan@126.com


OBJECTIVE: To investigate the clinical significance of the expression of PSMA (prostate specific membrane antigen), TERT (telomerase reverse transcriptase), and PDEF (prostate derived Ets factor) in malignant tumors of the prostate.

PATIENTS AND METHODS: The study was conducted with paraffin slices from 33 specimens of malignant tumors of the prostate and 17 of normal tissue. We found high levels of PSMA, TERT, and PDEF protein by Western blot and immunofluorescence in the malignant tumor of the prostate. We also detected upregulation of PSMA, TERT, and PDEF mRNA in the malignant tumor of the prostate, suggesting complex regulation of these three genes in prostate cancer.

RESULTS: Variance analysis showed statistically significant differences comparing the expression of PSMA, TERT, and PDEF in the malignant tumor of the prostate and normal tissues. The high expression of PSMA, TERT, and PDEF in the malignant tumor of the prostate suggests the important roles of these three factors in the occurrence and development of the malignant tumors of the prostate.

CONCLUSIONS: PSMA, TERT, and PDEF may serve as a reference for clinical diagnosis and as potential targets for the malignant tumor of the prostate therapeutics.

This article has been withdrawn. The Publisher apologizes for any inconvenience this may cause.

Free PDF Download

To cite this article

J. Situ, H. Zhang, L. Lu, K. Li, C. Hu, D.-J. Wang
Clinical significance of PSMA, TERT and PDEF in malignant tumors of the prostate

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 15
Pages: 3347-3352
DOI: